Hollings Cancer Center researchers have identified one reason why triple-negative breast cancer becomes resistant to ...

A team of MUSC Hollings Cancer Center researchers has discovered one way in which triple-negative breast cancer (TNBC) cells become resistant to immunotherapy and have tested a two-pronged treatment ...

One of the big presentations of this year’s ESMO (at least in our view) comes tomorrow morning bright and early. David Spigel ...

TNBC patients with pCRs had a 5-year event-free survival (EFS) rate of 92% with the addition of ICIs versus 88% without them.

By enabling subcutaneous administration for a cancer immunotherapy, Tecentriq Hybreza now offers patients with multiple cancer types and their physicians greater flexibility and choice of treatment ...

715MO); and 3.Exploratory analysis of patients with or without prior PD-(L)1 inhibitors in phase 3 OptiTROP-Breast01 study of ...

Gordon Campbell Like the arms race, the funding of new cancer drugs is an endless upwards spiral. First though, the good news ...

randomized Phase 3 study to evaluate 9MW2821 vs investigator's choice of chemotherapy in subjects with locally advanced or metastatic urothelial cancer who have previously received PD-(L ...

By enabling subcutaneous administration for a cancer immunotherapy, Tecentriq Hybreza now offers patients with multiple cancer types and their physicians greater flexibility and choice of treatment ...

1.Efficacy and ... or without prior PD-(L)1 inhibitors in phase 3 OptiTROP-Breast01 study of sac-TMT versus chemotherapy for previously treated advanced triple-negative breast cancer (TNBC ...

Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous (IV) Tecentriq1,2New subcutaneous (SC) op ...